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appear to increase proportionnally to the increase in LV mass, which may
allow to maintain coronary flow velocity and shear stress constant.
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Efficacy of Tranilast on Restenosis After Coronary
Angioplasty: is There Any Rebound Phenomenon
After Ceasing Tranilast at 3 Months?
Kinzo Ueda, Hideo Tamai, Yung-Sheng Hsu, Shinji Ono, Shozo Tanaka,
Kunihiko Kosuga, Masaharu Okada, Myou-u Wang, Seiichiro Motohara,
Hiromu Uehata. Shiga Medical Center for Adult Diseases, Moriyama, Japan
Restenosls: Clinical Trials and Observations
from which quantitative parameters are extracted. Our program provides re-
lational database organization and management functions for both images
and measurement data. In addition, it integrates database with our previously
developed image analysis programs for intravascular ultrasound (IVUS) and
coronary angiography.
The program runs in Microsoft Windows environment and does not require
specialized imaging hardware. Program consists of three functional mod-
ules: image database system, IVUS contour extraction/analysis module and
coronary angiography contour extraction/analysis module, Image database
system provides image retrieval, storage and display together with extracted
quantitative data. Each database record includes data on patient adminis-
tration, medical history and noninvasive test results. User is provided with
browse and search controls for database navigation, as well as with query
by example and lists and reports generation. Analysis programs are incorpo-
rated into the database through OLE (Object Linking and Embedding) tech-
nique, which enables user to launch appropriate image analysis program
simply by clicking the mouse over the chosen image. Extracted analysis
data are automatically stored in the appropriate database record. Further-
more, any other image processing/analysis Windows program that supports
OLE and can act as OLE server may be linked with the database by simple
Clipboard cut and paste operations. All images and data can be exported to
other Windows applications (text processors, spreadsheets, statistical and
data presentation software).
In practical testing the program proved to be user friendly, interactive and
flexible. It was particularly useful for integration of both images and quantita-
tive data obtained by coronary angiography and by IVUS, being helpful in the
validation of the latter technique, and providing better insight into the extent
and severity of coronary arteriosclerotic disease.
Tuesday, March 21,1995,2:00 p.m.-3:30 p.m.
Ernest N. Morial Convention Center, Room 103
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Tranilast, an anti-allergic drug, is also effective for the prevention of keloid.
We have already reported that 3 months (mos) administration of tranilast lim-
ited restenosis at 3 mos. To elucidate the efficacy of 3 mos administration
of tranilast for the prevention of restenosis at 6 mas after angioplasty, pa-
tients with stable effort angina were studied with following 3 conditions. (1 I
ACC/AHA type A lesion, (2) reference vessel diameter :::2.5 mm, (3) more
than 20% improvement of % stenosis after angioplasty with smooth dilata-
tion. One hundred lesions (group T) were treated with tranilast 600 mg/day
for 3 mos and administrations were ceased at the end of 3 mos. Control
group (group C) consists of 105 lesions matched with group T. Both group T
and C received antiplatelet agents, nitrates and Ca antagonists. Angiographic
follow-up was done at 3 and 6 mas after angioplasty. More than 50% loss
of % stenosis gained by angioplasty was defined as restenosis. Resu/ts: (1)
Changes in % stenosis: group T (vs group C); before angioplasty 73.4% ±
12.3% (71.1 % ± 11.5%, ns). immediately after angioplasty 12.8% ± 11.6%
(18.5% ± 11.0%, nsl, at 3 mos 25.8% ± 18.2% (33.2 ± 26.8%, P < 0.01). at
6 mos 22.0% ± 14.1 % (32.3% ± 21.4%, nsl. (2) Restenosis rate: group T (vs
C); at 3 mas 15.0% (38.1%, p < 0.01), at 6 mos 22.0% (45.7%, P < 0.01).
Conclusion: Group T showed lower restenosis rate at 3 mos and at 6 mos,
and ceasing tranilast at 3 mos did not increase the late restenosis rate. There
is no rebound phenomenon after ceasing tranilast treatment. Thus, 3 mos
administration of tranilast is sufficient to limit restenosis at 6 mos following
angioplasty.
1751-21 Combined Treatment with 3 Antiplatelet Agents
Reduces Neointimal Proliferation In Canine Coronary
Arteries After Angioplasty
H. Vernon Anderson, Janice McNatt, Kexin Cui, lowell Mower, Cory Martin, Jean
Pierre Maffrand, Fred DeClerck, Fred Clubb, L. Maximilian Suia, James
T. Willerson. University of Texas Medical School and Texas Heart Institute, Houston. TX
Platelet-derived growth factors are implicated in the neointimal prolifera-
tion (NP) that is partly responsible for restenosis after coronary angioplasty
QT Dispersion in Essential Hypertension
Cath-Lab Assistant: Integrated Image Analysis
and Relational Database Program
Imaging Workstations in Cardiology
A Multimedia Workstation for Real-time Review of
Full Size Angiographic and Echocardiographic
Image Sequences
laurence A. Spero, Bennett R. Groshong, Brian P Harrawood, Donald F. Fortin,
Thomas M. Bashore, Jack T. Cusma. Duke University Medical Center, Durham, North
Carolina
To fully implement a readily accessible imaging network for cardiovascular
studies in a busy clinical environment, we have developed a review station
for clinical use which can decompress, zoom, and display full resolution
(640 x 480) JPEG-encoded cardiac angiograms and echocardiograms (col-
orflow Doppler and 2-D) in real-time (30 frames/sec). These review stations
are networked to a digital image archival system and can be installed in mul-
tiple locations within a medical center. The review stations consist of a DEC
3000/600 AXP workstation with a DEC J300 Sight and Sound multimedia
board. An entire exam can be compressed to less than 10 Mbytes. A graphi-
cal user interface (GUll developed using OSF/Motif 1.2 enables a clinical user
to simultaneously display and control several image sequences. A sequence
can be retrieved in under three seconds and displayed dynamically in forward
or reverse directions with instantaneous speed control. Utilizing a commer-
cial relational database (Sybase), the GUI organizes image sequences for a
patient by image modality, location, time, and view. A schematic representa-
tion of cardiac anatomy derived from the clinical reporting system allows a
user to view specific angiographic image sequences by selecting appropri-
ate objects in the graphic display.
In situations where moderate reduction in image quality is acceptable,
these review stations, using compressed image sequences, provide rapid
access to a larger number of cases than would be otherwise possible. This
approach allows image sequences to be more readily distributed over a net-
work so they can be viewed by several workstations simultaneously. Real-
time image decompression provides a practical and clinically acceptable way
of maintaining ready access to large amounts of clinical cardiac images using
existing technology.
Tuesday, March 21, 1995, 1:30 p.m.-5:00 p.m.
Ernest N. Morial Convention Center, Hall B
Peter B.M. Clarkson, Abdul Naas, Catherine Macleod, Allan D. Struthers, Thomas
M. MacDonald. Department of Clinical Pharmacology; Ninewells Hospital & Medical
School, Dundee DDt 9SY, Scotland. UK
Increased OT dispersion (OTd) reflects regional variation in ventricular repo-
larisation, and has been shown in heart failure and hypertrophic cardiomy-
opathy to relate to an increased incidence of sudden death. As essential hy-
pertensives (EHI are also at increased risk of sudden death we aimed to de-
termine whether increased OTd is found in those EH who are known to be at
the highest risk of sudden death. In 50 EH we measured OTd (maximum cor-
rected aT interval minus minimum corrected aT interval), echocardiographic
left ventricular mass index (LVMI) (n = 46 as 4 patients non-echogenic), of-
fice systolic and diastolic blood pressure (SSP, DSP), and 24 hour ambulatory
systolic and diastolic blood pressure (24 SSP, 24 DSP) (n = 40). Univariate
analysis demonstrated no relationship between OTd and age, sex, height,
weight, 24 SSP or 24 DSR Significant relationships existed between OTd
and LVMI (R2 = 0.25, P < 0.001), SSP (R2 = 0.16, P < 0.01), DSP (R2 = 0.08,
P < 0.05). Multiple linear regression analysis revealed the only relationships
to OTd were LVMI (p < 0.01) and SSP (p < 0.05). Excluding 4 patients with
electro-cardiographic left ventricular hypertrophy (ECG-LVH) from the analy-
sis a significant relationship between OTd and LVMI (R2 = 0.13, P < 0.05)
and SSP (R2 = 0.10, P < 0.05) persists. These demonstrate that increased
OTd is found in EH with the highest risk of sudden death (greatest SSP and
LVMI). This relationship persists in the absence of ECG-LVH. Further study of
OTd, as a predictor of sudden death in EH is warranted.
Nenad Amodaj, Aleksandra Mojsilovic, Rade Babic 1, Mlodrag Ostojic 1,
Miodrag Popovic. Electrical Engineering Faculty. Belgrade, Yugoslavia; 1Institute for
Cardiovascular Diseases, Belgrade, Yugoslavia
Cardiac catheterization techniques deal with large amount of image data
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1751-31 Lovastatin and Probucol for the Prevention of
Restenosls After Coronary Angioplasty
groups in baseline clinical characteristics. The acute gain (0.96 ± 0.42 mm,
1.03 ± 0.40 mm) and late loss (0.36 ± 0.51 mm, 0.36 ± 0.57 mm) were
similar in the Fraxiparine and aspirin groups. Restenosis, defined as a binary
variable (stenosis >50% at angiographic follow-up) occurred in 41 % of the
Fraxiparine treated and 38% of the aspirin treated group (p = 0.69). At six
months major clinical event rates, death (1 % vs 2%), acute myocardial in-
farction (4% vs 2%1 and repeat revascularization 126% vs 26%) were similar
in both groups.
Despite, 3 days of pretreatment and 3 months of treatment with low
molecular weight heparin (Fraxiparine), no statistical differences were ob-
served in angiographic or clinical end points.
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Rapid Angiographlc Progression of "Target" and
"Non-target" Stenoses in Patients Awaiting Coronary
Angioplasty
Juan Carlos Kaski, Lilia Chen, Michael Chester. St. George's Hospital Medical School,
London, U.K.
Coronary angioplasty (PTCA) is effective therapy for angina pectoris but coro-
nary events occur after successful PTCA which may be caused by both
restenosis and progression of mild pre-existing, "non-target", stenoses. To
compare the short-term evolution of "target" versus "non-target" stenoses
in patients awaiting PTCA, we prospectively studied 161 consecutive sta-
ble angina patients (124 men and 37 women). After diagnostic angiography,
"target" stenoses for PTCA and "non-target" lesions were identified. Patients
were put on a routine waiting list and followed up regularly until repeat coro-
nary arteriography (mean ± SD: 7 ± 3 months). which was performed im-
mediately preceding angioplasty (138 patients) or soon after acute coronary
events (23 patients) when these occurred. Stenosis diameters were mea-
sured using computerized arteriography. Progression was defined as 2:20%
diameter reduction, new total occlusion, or development of "new" stenoses
2:30%. At study entry, diameters of target (n = 207) and non-target (n = 184)
lesions were 68 ± 9% and 38 ± 9%, respectively (p < 0.001). Disease pro-
gression occurred in 33 patients (20%). in whom 18 target (9%) and 15 non-
target stenoses (8%) progressed and 7 new lesions (1 total occlusion) devel-
oped. Total occlusion developed in 15 of the 18183%) target and in 6 of the
15 (40%) non-target stenoses; (p = 0.03). During follow up, 3 patients (2%)
had a myocardial infarction and 20 (12%) developed unstable angina. These
events were associated with progression of target stenoses in 10 patients,
of non-target stenoses in 7 patients, and with new lesions in one patient. In
5 patients events were not associated with stenosis progression.
Thus a similar proportion of target and non-target lesions progressed
rapidly. Target stenoses, however, were more likely to progress to total oc-
clusion than non-target lesions. Progression of non-target stenoses may con-
tribute to recurrence of angina and new coronary events after successful
angioplasty and their role should be considered when developing strategies
aimed at improving survival after angioplasty.
1751-61 Multiple Repeat Coronary Angioplasty for Final
Lesion Patency
Hidemasa Kitazume, Ichiro Kubo, Yoshio Ageishi, Toru Iwama, Akio Suzuki. Bokuto
Hospital, Tokyo, Japan
To demonstrate that multiple repeat coronary angioplasty can be solely uti-
lized to achieve final lesion patency after restenosis, such a protocol was
prospectively applied for restenosis since 1983. Bypass surgery was only
considered for 1) new left main trunk lesions, 21 symptomatic restenosis
where angioplasty was either unsuccessful or unsuitable, and 3) patient
preference. Between 1983 and 1992, 1455 lesions (acute myocardial infarc-
tion or total occlusion excluded) were successfully dilated for the first time.
Although only 941 (68%) of the 1385 lesions studied showed satisfactory
patency (:::70% stenosis) after the first procedure, 93% (1248/1345 stud-
ied) showed satisfactory patency after repeating angioplasty up to 3 times
and 94% (1268/1354 studied) after repetition up to 6 times. Only 23 lesions
11.6%) required 4 or more procedures and 20 of them showed final patency.
Disease aggravation (either impossible or failed repeat angioplasty, acute in-
farction, or sudden death) occurred in 43 lesions (3.2%). Bypass grafts were
done for 11 lesions of 7 patients, mostly due to disease progression at the
left main trunk.
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Bypass Surgery
Patricia G. Cavera, James H. O'Keefe, Jr., Gregg W. Stone, Ben D. McCallister, Jr.,
Cheryl Dreiling, Robert Ligon, Ray L. Kacich. Mid America Heart Institute, Kansas City,
MO
We hypothesized that combination lipid lowering therapy (Lovastatin) and
anti-oxidant (Probucol) therapy might reduce restenosis following coronary
angioplasty(pTCAI. To address this question, 239 patients (pts) were enrolled
in a multi-center, randomized trial whereby 2 out of 3 pts received Lovas-
tatin 20 mg bid and Probucol 500 mg bid in combination; lout of 3 pts was
randomized to double placebo. Pts were treated in a blinded fashion for 6
months. Total cholesterol (154 vs 211), LDL 198 vs 141) and HDL (31 vs 42)
were lower in treated compared with placebo patients. Serious adverse ef-
fects from the medications were not observed.
EVENTS WITHIN 6 MONTHS
Quantitative coronary angiography was available in 147 lesions, the mean
loss in luminal diameter was 27% ± 31 % and 28% ± 34% in treated and
placebo groups.
Conclusion: Combination Lovastatin and Probucol: 1) reduced total choles-
terol (27%). LDL (29%) and HDL (27%) levels, but 2) did not prevent resteno-
sis or clinical events during the first six months post-angioplasty.
(PTCA). Reducing platelet accumulation at PTCA sites may attenuate NP
and restenosis. Single antiplatelet agents are not effective, due to multiple
platelet activation pathways. Previous work suggested that combined antag-
onism of 2 mediators of platelet aggregation -thromboxane A2 (byridogre/)
and serotonin (by kemnserin). could reduce platelet-thrombus formation and
lessen NP We therefore tested the hypothesis that combined treatment with
3 agents (ridogrel, kemnserin. and an ADP antagonist - clopidogre/l would
be more effective in reducing NP after PTCA. We studied 18 dogs with coro-
nary flow probes and plastic constrictors chronically implanted on LAD arter-
ies. All dogs underwent LAD PTCA and were sacrificed after 8 weeks of mon-
itoring. Eight dogs were controls, while 10 dogs were treated with combined
anti platelet therapy for 3 weeks before and 3 weeks after PTCA. Compared to
controls, ex vivo platelet aggregation was virtually abolished in treated dogs,
and bleeding times during treatment were greater (>720 vs 119 ± 4 sec, p <
0.001). Cyclic flow variations (CFVs) after PTCA, from repetitive accumulation
and dislodgement of platelet aggregates at PTCA sites, occurred in 7/8 con-
trols but in only 1/10 treated dogs (p < 0.01). Platelet counts and hematocrit
values were not different between treated and control groups. Quantitative
coronary artery histology revealed that neointimal area was threefold less in
the treated group (0.18 ± 0.07 cm2 vs 0.52 ± 0.12, P = 0.032), as was the
percent lumen stenosis (13 ± 4% vs 40 ± 13%, P = 0.06).
Conclusion: Combination antiplatelet therapy with these 3 antagonists in-
hibited several relevant measures of platelet function and reduced neointi-
mal proliferation in a canine coronary artery angioplasty model.
Jean-Marc Lablanche, The FACT investigators. France, Belgium, Spain
Restenosis after coronary angioplasty is a multifactorial process that may
involve elastic recoil, thrombus incorporation, smooth muscle cell prolifera-
tion, and late vascular remodeling. Fraxiparine (nadroparin) is a low molecular
weight heparin derivative that has potent antithrombotic and antiproliferative
properties in animal models.
The FACT (Fraxiparine Angioplastie Coronaire Transluminale) study is a
multicentre double-blind randomised trial designed to compare the effects
of treatment with Fraxiparine or aspirin on the occurrence of restenosis af-
ter coronary balloon angioplasty. All patients received aspirin (250 mg, daily)
before coronary angioplasty. Therapeutic doses of unfractionated heparin
were used during coronary angioplasty in both groups. The active treatment
group received subcutaneous injections of Fraxiparine (0.6 ml) daily for 3
days before coronary angioplasty that was continued for 3 months. The con-
trol group was treated with aspirin (250 mg) daily for 3 months.
In total, 354 patients were randomized and constitute the intention-to-treat
population. Angiographic follow-up was performed in 91 % of patients with
successful procedures at 3 months. There were no differences between
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1751-41 Low Molecular Weight Heparin in the Prevention of
Restenosis After Coronary Angioplasty. Results of
the FACT Study
